Cipla Ltd share price logo

Cipla Ltd (CIPLA)


Get free price alerts. Set up your Free investment account to get Live Prices. >
Q3 '23 Results
News and Events

Cipla Ltd share Performance

  • ₹1,475.2
    downward going graph



    Day's Volatility:1.17%



    downward going graph
  • ₹935
    downward going graph



    52 Weeks Volatility:39.50%



    downward going graph
1 Month Return+ 5.57 %
3 Month Return-0.07 %
1 Year Return+ 55.45 %
Previous Close₹1,486.45
Upper Circuit-
Lower Circuit-
Market Cap₹1,20,015.23Cr

Analyst Rating

based on 34 analysts


Based on 34 analysts offering long term price targets for Cipla Ltd. An average target of ₹1471.44

Source: S&P Global Market Intelligence

Company Information

Cipla Ltd is an Indian multinational pharmaceutical and biotechnology company founded in 1935 by Dr. K.A. Hamied. It is headquartered in Mumbai, India and is one of the leading pharmaceutical companies in the world. Cipla has over 35000 employees and is present in 80+ countries. The company has a diversified product portfolio that includes active pharmaceutical ingredients (API), generics, OTC products, biosimilars, and nutraceuticals.

Cipla's operations include manufacturing, marketing, and distribution of pharmaceuticals, biotechnology, and consumer healthcare products. Its top products include respiratory, anti-infectives, cardiovascular, and oncology drugs. Popular brands include Asthalin, Cipcal, Cifran, and Erythromycin. Cipla also manufactures nutraceuticals, herbal products, and over-the-counter medicines.

Share Price: ₹1478.65 per share as on 27 May, 2024 04:01 PM
Market Capitalisation: ₹1,20,015.23Cr as of today
Revenue: ₹6,082.37Cr as on March 2024 (Q1 24)
Net Profit: ₹934.40Cr as on March 2024 (Q1 24)
Listing date: 03 Nov, 1994
Chairperson Name: Y K Hamied
OrganisationCipla Ltd
E-voting on sharesClick here to vote

Key events for Cipla Ltd

  • Cipla Stock Declines Due to Increased Competition - 23 May, 2024

    Cipla and Lupin stocks declined by up to 7% after US-based Amphastar received approval for its Albuterol Sulfate Inhalation Aerosol, which is expected to cause price erosion. However, Cipla shares have risen 20% this year. recommends buying Cipla stock.

  • Cipla Receives Final Approval for Generic Version of Hormonal Tumor Treatment Drug - 22 May, 2024

    Cipla's wholly-owned subsidiary, Cipla USA Inc., has received final approval from the USFDA for its Abbreviated New Drug Application (ANDA) for Lanreotide Injection. The drug is indicated for the treatment of patients with acromegaly and gastroenteropancreatic neuroendocrine tumors.

  • Cipla Ltd to Increase Dividend Payment - 21 May, 2024

    Cipla Limited has announced an increased dividend payment of ₹13.00, up from last year's comparable dividend. The company is easily earning enough to cover its dividend payments and it is great to see that these earnings are being translated into cash flow. With a growing EPS and stable dividend history, Cipla is a strong income stock.

  • Cipla Receives Positive Recommendations and Involved in Major Block Deals - 17 May, 2024

    Cipla receives positive recommendations from Motilal Oswal Financial Services, projecting a potential upside of 13.88%. An HNI based out of suburban Mumbai has been involved in major block deals, including Cipla.

  • Cipla Reports Mixed Q4 Results, Promoters Sell Stake & Invests in Achira Labs - 16 May, 2024

    Cipla reports mixed Q4 results with revenue growth from core markets and larger brands. Promoters sell 2.53% stake for Rs 2,750 crore while ICICI Prudential MF buys Rs 743 crore worth of shares. Cipla invests an additional Rs 26 crore in Achira Labs.

  • Cipla Promoter Stake Sale & Investment in Associate Company - 15 May, 2024

    Cipla's promoters sold a 2.53% stake worth Rs 2,750 crore via block deals while KR Choksey recommended buying the stock with a target price of Rs 1633/share. Additionally, Cipla entered into definitive agreements for further investment of up to Rs 26 crore in Achira Labs.

  • Cipla Promoters Plan to Sell Stake Worth Rs 2637 Crore - 14 May, 2024

    Cipla's promoter family and Okasa Pharma are set to sell 2.53% stake worth Rs 2637 crore in the company through block deals on May 15. Prabhudas Lilladher recommends accumulating Cipla stock with a target price of Rs 1405.

  • Cipla Reports Strong Q4FY24 Results - 13 May, 2024

    Cipla Ltd reported a 79% YoY increase in Q4FY24 net profit to Rs 939.04 crore, while its consolidated revenue rose 7.4% YoY to Rs 6,163.24 crore. The company's board recommended a final dividend of Rs 13 per equity share for FY24. Numerous brokerages revised their target price on Cipla shares after the Q4FY24 results. Despite slightly missing expectations, Cipla's strong US pipeline and steady Q4 earnings drove bullishness.

  • Cipla Reports Strong Financial Results for FY2024 and Q4 - 12 May, 2024

    Cipla reports strong financial results for FY2024, with a 47% increase in net income and a 16% profit margin. The company's Q4 results show a 7.39% YoY increase in revenue and 78.64% YoY increase in profit. However, shares are down 6% from last week.

  • Cipla Reports Strong Q4 Results and Dividend Announcement - 10 May, 2024

    Cipla Ltd reports a strong Q4FY24 performance with a 79% YoY increase in net profit and a 10% YoY rise in revenue from operations. The company also declares a final dividend of Rs 13 per equity share for FY24. Despite the positive results, Cipla's shares fell 1.4% on May 10th due to lower-than-expected revenue.

  • Cipla Expected to Report Healthy Q4 Results Despite USFDA Observation - 09 May, 2024

    Cipla is expected to report a healthy Q4 result with an increase in revenue and profits. However, Cipla has received one observation from USFDA for its Kurkumbh facility.

  • Cipla Receives Observation from USFDA - 08 May, 2024

    Pharmaceutical company Cipla has received one inspectional observation in Form 483 from the US health regulator for its manufacturing facility located in Kurkumbh, Maharashtra. The company is committed to addressing this observation comprehensively within the stipulated time.

  • Cipla Recalls Inhalation Solution Due to Manufacturing Issues; Demonstrates Robust Uptrend - 06 May, 2024

    Cipla is recalling inhalation solution from the US market due to manufacturing issues. Meanwhile, Cipla's stock has demonstrated a robust uptrend on a weekly scale, indicating sustained upward momentum and bullish sentiment.

  • Cipla Recalls Asthma Medication in the US - 05 May, 2024

    Cipla's New Jersey-based subsidiary is recalling over 59,000 packs of asthma medication from the US market due to manufacturing issues related to short fill. The recalled drug is used to help control the symptoms of lung diseases.

  • Cipla Ltd Shows Strong Growth and Insider Interest - 03 May, 2024

    Cipla Ltd has shown strong growth in EPS, EBIT margins, and revenues over the past three years. Company insiders have also invested meaningfully in the stock, making it worth watching for investors.

  • Indian Pharma Companies to Benefit from Patent Cliff and Short Supply of Key Drugs - 02 May, 2024

    Unmesh Sharma, Head of Institutional Equities at HDFC Securities, expects Sun Pharma, Dr Reddys Labs, Cipla and Aurobindo Pharma to benefit from the patent cliff and short supply of key drugs due to suboptimal profitability, creating incremental revenue opportunities for Indian players.

  • Cipla Stock Analysis & Trading Strategies - 30 Apr, 2024

    Cipla's stock is in a long-term uptrend and expected to reach the Rs 1,500 resistance level. Traders can buy now at Rs 1,407 and deploy a Debit Spread strategy suggested by Madhu Bansal for steady income. Maximum profit stands at Rs 34,000 with maximum loss at Rs 17,500.

  • Cipla Subsidiary Completes Purchase of Distribution Business - 29 Apr, 2024

    Cipla Health, a wholly-owned subsidiary of Cipla Ltd, has completed the purchase of the distribution and marketing business undertaking of cosmetics and personal care business from Ivia Beaute Private Limited through a slump sale arrangement.

  • Investec Initiates Long FAST on Cipla Stock - 25 Apr, 2024

    Investec has initiated a long FAST on Cipla stock, citing key pipeline assets delivery and improvement in US generic macro. Despite anticipation of weak Q4 results and competition from Amneal, Cipla remains Investec's preferred pick in the largecap pharma space.

  • Investec Maintains Buy Rating on Cipla with Raised Target Price - 24 Apr, 2024

    Brokerage firm Investec maintains a buy rating on Cipla despite the recent decline in its stock value due to anticipation surrounding Amneal's potential entry into the market with a competitive offering of Albuterol. Investec sees limited impact on EPS even in the face of new competition and envisions the possibility of upgrades for FY25 and FY26. The brokerage firm has raised the target price to Rs 1550 per share.

Fundamentals of Cipla Ltd

Insights on Cipla Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.


    FII Holding Up


    Foreign Institutions have increased holdings from 25.68% to 25.77% in Mar 2024 quarter


    MF Holding Up


    Mutual Funds have increased holdings from 16.63% to 16.79% in Mar 2024 quarter


    Price Rise


    In the last 7 days, CIPLA stock has moved up by 3.1%

  • imgNO EFFECT

    Against Peers


    In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 112.5% return, outperforming this stock by 54.8%

  • imgNO EFFECT

    Promoter Holding Unchanged


    Promoters holdings remained unchanged at 33.40% of holdings in Mar 2024 quarter

  • imgNO EFFECT

    Against Peers


    In the last 1 year, Zydus Lifesciences Ltd has given 110.1% return, outperforming this stock by 54.7%


    Retail Holding Down


    Retail Investor have decreased holdings from 16.43% to 16.25% in Mar 2024 quarter


    Profit Down


    Netprofit is down for the last 3 quarters, 1.13K Cr → 939.04 Cr (in ₹), with an average decrease of 8.9% per quarter


    Revenue Fall


    Revenue is down for the last 3 quarters, 6.85K Cr → 6.41K Cr (in ₹), with an average decrease of 3.3% per quarter

Cipla Ltd Valuation

Cipla Ltd in the last 5 years

  • Overview

  • Trends

Lowest (18.11x)

March 19, 2020

Today (29.11x)

May 24, 2024

Industry (62.95x)

May 24, 2024

Highest (42.80x)

January 23, 2018


Mutual Fund Holdings

Funds Holdings
HDFC Flexi Cap Fund -Direct Plan - Growth OptionHDFC Flexi Cap Fund -Direct Plan - Growth Option5.03%
SBI Equity Hybrid Fund Direct GrowthSBI Equity Hybrid Fund Direct Growth1.54%
HDFC ELSS TaxSaver -Direct Plan - Growth OptionHDFC ELSS TaxSaver -Direct Plan - Growth Option5.03%
Parag Parikh Flexi Cap Direct GrowthParag Parikh Flexi Cap Direct Growth0.91%
Kotak Flexicap Fund Direct GrowthKotak Flexicap Fund Direct Growth1.21%

Shareholding Pattern

InvestorsHoldings %Prev. 1 periods3M change
Promoter Holdings
Foreign Institutions
Mutual Funds
Retail Investors

Technicals of Cipla Ltd share

News & Events of Cipla Ltd


Cipla latest to get oppn dose, scraps out-of-Goa hiring | Goa News

Panaji: After coming under fire for planning a recruitment drive in Vapi, Gujarat, for vacancies at its Goa production facility, Cipla Ltd announced t.

26 May, 2024 12:28 AM

Cipla Share Price Target 2024: Dividend in Q4 Results - Buy, Sell or Hold?

Cipla Share Price Target 2024: Geojit remains positive on the Cipla’s stock and said that the substantial progress across key markets, a robust pipeline of inno... Read more

26 May, 2024 03:23 PM

Cipla Stocks Live Updates: Cipla Closes at Rs 1486.45 with Below-Average Trading Volume

Stay updated with the Cipla Stock Liveblog, your one-stop destination for real-time information and analysis of a leading stock. Explore the latest updates on C... Read more

27 May, 2024 08:32 AM
View More

Frequently Asked Questions

  • Get a PAN card.
  • Open a Demat account.
  • Open a Trading account.
  • Link your Demat account to your Trading account.
  • Fund your Trading account.
  • Place an order to buy Cipla Ltd shares.

Cipla Ltd (CIPLA) share price today is ₹1478.65

Cipla Ltd is listed on NSE

Cipla Ltd is listed on BSE

  • Today’s highest price of Cipla Ltd is ₹1492.55.
  • Today’s lowest price of Cipla Ltd is ₹1475.2.

PE Ratio of Cipla Ltd is 29.11

PE ratio = Cipla Ltd Market price per share / Cipla Ltd Earnings per share

Today’s traded volume of Cipla Ltd(CIPLA) is 13.93L.

Today’s market capitalisation of Cipla Ltd(CIPLA) is ₹120015.23Cr.

Cipla Ltd(CIPLAPrice
52 Week High
52 Week Low

Cipla Ltd(CIPLA) share price is ₹1478.65. It is down -2.66% from its 52 Week High price of ₹1519

Cipla Ltd(CIPLA) share price is ₹1478.65. It is up 58.14% from its 52 Week Low price of ₹935

Cipla Ltd(CIPLAReturns
1 Day Returns
1 Month Returns
3 Month Returns
1 Year Returns